Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silo Pharma (SILO) Cash & Equivalents (2019 - 2025)

Silo Pharma's Cash & Equivalents history spans 7 years, with the latest figure at $3.9 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 19.41% year-over-year to $3.9 million; the TTM value through Sep 2025 reached $3.9 million, down 19.41%, while the annual FY2024 figure was $3.9 million, 10.82% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $3.9 million at Silo Pharma, down from $4.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $12.3 million in Q3 2022 and bottomed at $158832.0 in Q2 2023.
  • The 5-year median for Cash & Equivalents is $4.5 million (2024), against an average of $5.6 million.
  • The largest annual shift saw Cash & Equivalents soared 50611.35% in 2021 before it tumbled 98.37% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $9.8 million in 2021, then rose by 15.55% to $11.4 million in 2022, then crashed by 69.0% to $3.5 million in 2023, then rose by 10.82% to $3.9 million in 2024, then grew by 0.3% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for SILO's Cash & Equivalents are $3.9 million (Q3 2025), $4.3 million (Q2 2025), and $3.1 million (Q1 2025).